Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center’s pre-operative evaluation, patient characteristics and outcomes of male LAs patients requiring pituitary surgery. Methods: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAs patients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted. Results: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75% vs. 44.7% p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6% vs. 42.1%, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9% vs. 24.1%, p = NS) and radiation therapy (18.4% vs. 19.4%, p = NS). Conclusions: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalPituitary
DOIs
StateAccepted/In press - Jun 23 2018

Fingerprint

Prolactinoma
ACTH-Secreting Pituitary Adenoma
Residual Neoplasm
Pituitary Neoplasms
Optic Chiasm
Hypogonadism
Pituitary Hormones
Radiotherapy

Keywords

  • Corticotroph adenomas
  • Dopamine agonist intolerance
  • Dopamine agonist resistance
  • Lactotroph adenomas
  • Males
  • Prolactinomas

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{4e31858fb06e41a5939bfa46de20fe95,
title = "Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study",
abstract = "Purpose: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center’s pre-operative evaluation, patient characteristics and outcomes of male LAs patients requiring pituitary surgery. Methods: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAs patients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted. Results: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75{\%} vs. 44.7{\%} p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6{\%} vs. 42.1{\%}, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9{\%} vs. 24.1{\%}, p = NS) and radiation therapy (18.4{\%} vs. 19.4{\%}, p = NS). Conclusions: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.",
keywords = "Corticotroph adenomas, Dopamine agonist intolerance, Dopamine agonist resistance, Lactotroph adenomas, Males, Prolactinomas",
author = "Winnie Liu and Roula Zahr and Shirley McCartney and Justin Cetas and Aclan Dogan and Maria Fleseriu",
year = "2018",
month = "6",
day = "23",
doi = "10.1007/s11102-018-0898-y",
language = "English (US)",
pages = "1--9",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery

T2 - a retrospective single center study

AU - Liu, Winnie

AU - Zahr, Roula

AU - McCartney, Shirley

AU - Cetas, Justin

AU - Dogan, Aclan

AU - Fleseriu, Maria

PY - 2018/6/23

Y1 - 2018/6/23

N2 - Purpose: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center’s pre-operative evaluation, patient characteristics and outcomes of male LAs patients requiring pituitary surgery. Methods: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAs patients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted. Results: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75% vs. 44.7% p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6% vs. 42.1%, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9% vs. 24.1%, p = NS) and radiation therapy (18.4% vs. 19.4%, p = NS). Conclusions: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.

AB - Purpose: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center’s pre-operative evaluation, patient characteristics and outcomes of male LAs patients requiring pituitary surgery. Methods: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAs patients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted. Results: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75% vs. 44.7% p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6% vs. 42.1%, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9% vs. 24.1%, p = NS) and radiation therapy (18.4% vs. 19.4%, p = NS). Conclusions: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.

KW - Corticotroph adenomas

KW - Dopamine agonist intolerance

KW - Dopamine agonist resistance

KW - Lactotroph adenomas

KW - Males

KW - Prolactinomas

UR - http://www.scopus.com/inward/record.url?scp=85049054138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049054138&partnerID=8YFLogxK

U2 - 10.1007/s11102-018-0898-y

DO - 10.1007/s11102-018-0898-y

M3 - Article

C2 - 29936681

AN - SCOPUS:85049054138

SP - 1

EP - 9

JO - Pituitary

JF - Pituitary

SN - 1386-341X

ER -